Corvus pharmaceuticals, inc. (CRVS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-12,935

-11,047

-11,004

-12,978

-11,643

-10,509

-10,498

-11,631

-14,301

-11,929

-12,717

-14,981

-16,036

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,347

-

-3,151

-20,232

-1,913

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

184

185

186

186

186

180

228

220

219

219

211

208

204

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

159

144

106

-

55

35

1

Accretion related to marketable securities

-64

-79

-181

-214

-170

-171

-205

-188

-44

-18

-64

-94

-19

129

209

205

105

-

-

-

-

Stock-based compensation

1,845

1,748

1,749

1,898

1,953

1,805

1,794

1,735

1,801

1,739

1,501

1,521

1,468

1,047

1,264

1,076

441

286

122

18

2

Change in fair value of convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

17,900

-300

Other

-

-

-

-

-

-

116

114

115

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid and other current assets

-226

-49

106

108

205

-895

699

-44

53

39

-179

247

-63

223

-429

-431

347

501

561

5

198

Operating lease right-of-use asset

-164

-

-

-

-146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

0

0

-1

51

0

-729

129

194

-

-

-

-

0

250

19

600

-

-252

40

-20

Accounts payable

908

538

-728

374

266

113

-370

-1,244

45

-158

-610

1,763

559

-613

1,002

322

-193

797

143

271

29

Accrued and other liabilities

530

299

-484

1,501

714

-813

-1,660

418

1,597

-876

1,025

229

1,121

1,006

888

302

618

1,076

-214

281

75

Operating lease liability

-211

-

-

-

-186

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-106

-110

-110

-108

148

-89

55

581

-

-

-

-

Net cash used in operating activities

-9,353

-8,510

-10,607

-9,214

-8,990

-8,257

-10,797

-10,889

-11,045

-10,979

-10,774

-11,711

-12,748

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,636

-

-3,352

-1,714

-2,324

Cash flows from investing activities
Purchases of marketable securities

11,411

23,713

50,371

34,599

29,903

32,056

30,350

83,658

15,797

13,236

28,001

29,060

18,012

-

-

-

-

-

-

-

-

Sales of marketable securities

1,009

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,983

61,657

91,133

-

-

-

-

Maturities of marketable securities

38,099

28,313

39,850

35,015

38,688

38,725

53,820

20,056

19,423

23,901

48,700

64,500

36,300

98,800

20,000

61,925

33,000

-

-

-

-

Purchases of property and equipment

-

5

4

0

16

135

160

54

6

-8

42

121

111

613

99

873

614

864

6

553

324

Net cash provided by investing activities

27,697

4,595

-10,525

416

8,769

6,534

23,310

-63,656

3,620

10,673

20,657

35,319

18,177

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-58,747

-

5,394

-26,275

-324

Cash flows from financing activities
Proceeds from issuance of common stock, net (includes $30,850 in aggregate gross proceeds from related parties for the year ended December 31, 2018)

-

-

-

-

-

0

0

0

64,877

-

-

-

-

-1

0

7,012

64,343

-

-

-

-

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

74,839

16,735

3,995

Proceeds from exercise of common stock options

-

2

16

5

1

172

166

48

7

597

126

0

8

-

-

-

-

0

66

0

42

Net cash provided by financing activities

-

2

16

5

1

172

166

48

64,884

1,308

126

0

8

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

18,344

-3,913

-21,116

-8,793

-220

-1,551

12,679

-74,497

57,459

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64,343

-

74,905

16,735

4,037

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

5,437

-

1,233

278

-40

-75,494

76,947

-11,254

1,389

Supplemental disclosures of cash flow information
Purchases of property and equipment incurred but not paid

-

-

-

-

16

-

-

-

-

-

-

-

46

-38

111

-188

199

128

149

-51

60

IPO costs incurred but not paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

301

-

-

-

-

Convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,300